Immunovant Files Automatic Shelf Registration Statement
Immunovant, Inc. has filed an automatic shelf registration statement (S-3ASR) with the SEC, allowing for the potential future offering of securities.
Stocks · News reference
Filed: 2026-11-09 AccNo: 0001764013-26-000121 Size: 300 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Immunovant, Inc. has filed an automatic shelf registration statement (S-3ASR) with the SEC, allowing for the potential future offering of securities.
Truist Securities has raised its price target for Immunovant, Inc. from $30.00 to $33.00 while maintaining a 'Hold' rating on the stock.
Immunovant reports positive trial results for IMVT-1402 in rheumatoid arthritis and plans FDA discussions on a registrational pathway.